Oculis (NASDAQ:OCS) Stock Price Down 2.5% - What's Next?

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) dropped 2.5% on Tuesday . The stock traded as low as $17.84 and last traded at $17.66. Approximately 4,525 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 46,251 shares. The stock had previously closed at $18.12.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OCS. Chardan Capital reaffirmed a "buy" rating and issued a $28.00 price target on shares of Oculis in a research note on Thursday, April 17th. HC Wainwright upped their target price on shares of Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th. Finally, Robert W. Baird lifted their price target on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th.

Oculis Price Performance

The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $772.38 million, a P/E ratio of -9.17 and a beta of 0.19. The stock has a fifty day moving average of $18.76 and a 200-day moving average of $18.09.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Equities analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Hedge funds have recently added to or reduced their stakes in the stock. abrdn plc raised its position in shares of Oculis by 23.0% in the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after acquiring an additional 188,871 shares during the period. Geode Capital Management LLC boosted its position in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Oculis in the 4th quarter valued at $225,000. Bellevue Group AG acquired a new stake in Oculis during the 4th quarter worth $170,000. Finally, Bank of America Corp DE lifted its holdings in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.